Effects of miglitol in platelet-derived microparticle, adiponectin, and selectin level in patients with type 2 diabetes mellitus by Nomura, Shosaku et al.
© 2011 Nomura et al, publisher and licensee Dove Medical Press Ltd.   This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of General Medicine 2011:4 539–545
International Journal of General Medicine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
539
OrIGINAL reseArch
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/IJGM.S22115
effects of miglitol in platelet-derived microparticle, 
adiponectin, and selectin level in patients with 
type 2 diabetes mellitus
shosaku Nomura1
seitaro Omoto2
Takashi Yokoi1
shinya Fujita1
ryotaro Ozasa1
Noritaka eguchi3
Akira shouzu3
1First Department of Internal 
Medicine, Kansai Medical University, 
2Division of Internal Medicine, 
Korigaoka Yukeikai hospital, 3Division 
of Internal Medicine, saiseikai Izuo 
hospital, Osaka, Japan
correspondence: shosaku Nomura 
First Department of Internal Medicine, 
Kansai Medical University, 10–15 
Fumizono-cho, Moriguchi, Osaka  
570-8507, Japan 
Tel +81 6 6993 9453 
Fax +81 6 6992 1293 
email shosaku-n@mbp.ocn.ne.jp
Background: Platelet-derived microparticles (PDMP), selectins, and adiponectin play an 
important role in the development of atherosclerosis in diabetes. Miglitol has been shown to 
have a beneficial effect on postprandial hyperglycemia in diabetic patients. However, its influ-
ence on platelet activation markers (PDMP and soluble CD40 ligand [sCD40L]), selectins, and 
adiponectin in these patients is poorly understood.
Aim: We investigated the effect of miglitol on circulating levels of PDMP, sCD40L, selectins, 
and adiponectin in patients with type 2 diabetes.
Methods: Miglitol (150 mg/day) was administered for 4 months. Levels of PDMP, sCD40L, 
soluble P-selectin (sP-selectin), soluble E-selectin (sE-selectin), soluble L-selectin (sL-selectin), 
and adiponectin were measured by enzyme-linked immunosorbent assay at baseline, and after 1 
and 4 months of treatment.
Results: The levels of PDMP, sCD40L, sP-selectin, sE-selectin, and sL-selectin were higher 
in diabetic patients than in hypertensive patients, while there were no significant differences 
between hypertensive and hyperlipidemic patients. Before miglitol treatment, the adiponectin 
level of diabetic patients was lower than that of hypertensive patients. Miglitol therapy signifi-
cantly decreased the plasma PDMP and sCD40L levels relative to baseline. Miglitol also caused 
a significant decrease of sP-selectin, sE-selectin, and sL-selectin. On the other hand, miglitol 
therapy led to a significant increase in adiponectin after 4 months of administration compared 
with baseline. Furthermore, the reduction of platelet activation markers and selectins during 
miglitol therapy was significantly greater in the responder (adiponectin-improved) group than 
the nonresponder group of diabetic patients.
Conclusion: Miglitol has an adiponectin-dependent anti-atherothrombotic effect that may be 
beneficial for primary prevention of atherothrombosis in patients with type 2 diabetes.
Keywords: platelet activation markers, atherothrombosis, platelet-derived microparticles, 
PDMP
Introduction
Diabetic patients develop hypercoagulability and platelet hyperaggregability,1,2 along 
with increased levels of platelet activation markers such as platelet-derived micropar-
ticles (PDMP).3 Expression of cell adhesion molecules is also increased in diabetes,4 
and these molecules have been suggested to have a role in the microvascular compli-
cation of this disease. P-selectin is an adhesion molecule that is involved in adhesion 
of platelets to leukocytes or the endothelium.5 Serum levels of soluble P-selectin 
(sP-selectin) are elevated in patients with diabetes.6,7 The first step in the process 
of leukocyte migration into the subendothelial space is the adhesion of circulating International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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  leukocytes to the endothelium, which may involve adhesion 
molecules like L-selectin and can eventually lead to vascular 
complications.
A large volume of epidemiological data indicates that 
persons with postprandial hyperglycemia have an increased 
risk of cardiovascular disease.8,9 Patients with postprandial 
hyperglycemia often have accompanying postprandial 
hyperinsulinemia. However, the postprandial rise in blood 
glucose itself is now considered to be a risk factor for the 
progression of atherosclerosis.10,11 α-Glucosidase inhibitors 
(α-GI) such as acarbose have shown long-term beneficial 
and protective effects against atherosclerosis. The Study 
to Prevent Non-Insulin-Dependent Diabetes Mellitus 
(STOP-NIDDM) trial demonstrated that treatment with 
acarbose reduces the onset of diabetes and the incidence 
of cardiovascular disease and new hypertension in patients 
with impaired glucose tolerance.12–14 A meta-analysis of 
seven long-term studies has also shown that acarbose pre-
vents myocardial infarction and cardiovascular disease in 
patients with type 2 diabetes.15 These findings suggest that 
inhibition of postprandial hyperglycemia by α-GI may 
be a promising therapeutic strategy for the prevention of 
cardiovascular disease in patients with impaired glucose 
tolerance and/or diabetes.
Miglitol, another α-GI, has unique pharmacokinetics.16 
After oral administration, it is rapidly and completely 
absorbed, even at a high dose, from the small intestines,16 
even though other α-GIs are scarcely absorbed there. 
These pharmacokinetics enable early-phase suppression 
of postprandial glucose elevation with a decrease in the 
severity of gastrointestinal complications, even at high 
doses, because absorption of carbohydrates is very low in 
the lower small intestine where miglitol is concentrated. 
However, the effects of miglitol on platelet activation 
markers, selectins, and adiponectin in patients with type 2 
diabetes are poorly understood. Therefore, this study was 
performed to investigate the effects of miglitol on platelet 
activation markers, selectins, and adiponectin in type 2 
diabetic patients.
Methods
Patients
The subjects included 72 nondiabetic (37 patients with 
hypertension and 35 patients with hyperlipidemia) and 
38 diabetic patients (Table 1). Between April 2007 and 
November 2009, patients were selected from among those 
admitted to our hospital for the treatment of hypertension, 
hyperlipidemia, and diabetes. The study protocol was 
approved by our   Institutional Review Board, and written 
informed consent was obtained from each patient prior to 
starting the trial. A history (within 3 months prior to enrol-
ment) of inflammatory disease, coronary artery disease, or 
cerebrovascular disease was not permitted. Clinically detect-
able renal   dysfunction (serum creatinine $2.0 mg/dL), hepatic 
dysfunction (elevated transaminases), infection (fever or 
elevated white blood cell count), or malignancy (detected by 
ultrasound or computed tomography) were also not permit-
ted. Ten patients were taking aspirin because of old cerebral 
infarction or angina pectoris, while 39 patients were using 
angiotensin II receptor blockers (ARBs), and 24 patients were 
taking Ca antagonists for hypertension (Table 1). There were 
also 27 patients taking statins for hyperlipidemia. The doses of 
prior drugs such as aspirin, statins, ARBs, and   Ca-antagonists 
were not adjusted during the present study.
study design
Miglitol (150 mg/day) was administered for 4 months to 
randomly selected patients. There were no other changes to 
drug therapy during the treatment. Clinical and biochemi-
cal data were obtained before and after starting acarbose 
administration.
Table 1 Baseline characteristics of the study population
Hypertension Hyperlipidemia Diabetes
Number of patients 37 35 38
Gender (male/female) 21/16 18/17 20/18
Age, years 61 ± 4 62 ± 7 63 ± 6
BMI, kg/m2 25.2 ± 3.1 26.6 ± 4.5 27.6 ± 4.3
Tc, mg/dL 198 ± 41 245 ± 19 235 ± 32
TG, mg/dL 140 ± 25 242 ± 43 228 ± 35
hDL-c, mg/dL 51 ± 11 46 ± 13 45 ± 11
LDL-c, mg/dL 119 ± 25 152 ± 37 143 ± 40
hbA1c (%) 4.8 ± 0.5 5.2 ± 1.3 7.5 ± 1.4
complications, n (%)
  Angina pectoris 6 (16.2) 3 (8.6) 5 (13.2)
  heart failure 3 (8.1) 2 (5.7) 2 (5.3)
  cerebral infarction 1 (2.7) 2 (5.7) 3 (7.9)
  hypertension – 5 (14.3) 7 (18.4)
  hyperlipidemia 4 (10.8) – 3 (7.9)
  Diabetes mellitus 0 (0) 0 (0) –
Medications, n (%)
  Aspirin 3 (8.1) 1 (2.9) 5 (13.2)
  statins 5 (13.5) 20 (57.1) 2 (5.3)
  ArBs 25 (67.6) 8 (22.9) 6 (15.8)
  ca antagonists 18 (48.6) 2 (5.7) 4 (10.5)
Note: Data are shown as mean ± standard deviation.
Abbreviations: BMI, body mass index; Tc, total cholesterol; TG, triglyceride; 
hDL-c,  high-density  lipoprotein  cholesterol;  LDL-c,  low-density  lipoprotein 
cholesterol; hbA1c, hemoglobin A1c; ArB, angiotensin II receptor blocker.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Measurement of platelet-derived 
microparticles
An enzyme-linked immunosorbent assay (ELISA) kit for the 
detection of PDMPs17–19 was obtained from Jimro Co, Ltd 
(Tokyo, Japan). Briefly, a blood sample was collected from a 
peripheral vein into a vacutainer containing EDTA-ACD (eth-
ylenediaminetetraacetic acid–acid citrate dextrose solution) 
(Nipro Co Ltd, Japan) with a 21-gauge needle to minimize 
platelet activation. The sample was gently mixed by inverting 
the tube once or twice and then left at room temperature for 
2–3 hours, followed by centrifugation at 8000 g for 5 minutes 
at room temperature. Immediately after centrifugation, we 
collected 200 µL of the upper layer of supernatant from a 
2-mL sample to avoid contamination and stored each sample 
at -40°C until analysis. The results of the ELISA performed 
under the current experimental conditions were reproduc-
ible. PDMPs were measured twice, and the mean value was 
calculated. The kit employed two monoclonal antibodies 
directed against platelet glycoproteins CD42b and CD42a 
(glycoprotein Ib and IX). One U/mL of PDMP was defined 
as 24,000 solubilized platelets/mL in this ELISA.
Measurement of adiponectin, soluble 
cD40 ligand (scD40L), sP-selectin, 
soluble e-selectin (se-selectin), and 
soluble L-selectin (sL-selectin)
Blood samples from patients and controls were collected 
into tubes containing sodium citrate or tubes without anti-
coagulant and were allowed to clot at room temperature for 
a minimum of 1 hour. Serum or citrated plasma was then 
isolated by centrifugation for 20 minutes at 1000 g (4°C) and 
stored at -30°C until analysis with an   adiponectin ELISA kit 
(Otsuka Pharmaceuticals Co Ltd, Tokyo, Japan). sCD40L, 
sP-selectin, sE-selectin, and sL-selectin were measured with 
a monoclonal antibody-based ELISA kit from BioSource 
International Inc (Camarillo, CA). The recombinant products 
and standard solutions provided with the kits were used as 
positive controls in each assay, and procedures were done 
according to the manufacturers’ instructions.
statistics
Data are expressed as the mean ± standard deviation and 
were analyzed by two-factor analysis of variance (ANOVA) 
for repeated measures, as it was appropriate. Between-group 
comparisons were made with the Bonferroni test, and within-
group differences were assessed with Student’s paired t-test. 
The level of significance was P , 0.05.
Results
When baseline values before treatment were compared 
among the three patient groups, no significant differences 
were noted for any of the parameters (Table 1).
The levels of PDMP, sCD40L, sE-selectin, sP-selectin, 
and sL-selectin were higher in diabetic patients than in hyper-
tensive patients (Table 2). However, there were no significant 
differences between the hypertensive and hyperlipidemic 
patients. Before miglitol treatment, adiponectin levels were 
lower in the diabetic patients than the hypertensive patients 
(Table 2). There were no significant differences between 
the hypertensive and hyperlipidemic patients with respect 
to PDMP, sCD40L, sP-selectin, sE-selectin, and sL-selectin, 
although they showed a slight difference for adiponectin 
(Table 2).
Miglitol therapy significantly decreased the plasma 
PDMP level relative to baseline (before vs 1 month 
vs 4 months; 21.2 ± 7.6 vs 18.2 ± 8.5 vs 15.4 ± 6.5 U/mL; 
1 month, not significant [NS]; 4 months, P , 0.01) (  Figure 1). 
Miglitol also caused a significant decrease in sCD40L 
(before vs 1 month vs 4 months; 3.1 ± 1.2 vs 2.8 ± 1.1 
vs 2.3 ± 0.9 ng/mL; 1 month, NS; 4 months, P , 0.05), 
sP-selectin (before vs 1 month vs 4 months; 213 ± 98 vs 
194 ± 73 vs 162 ± 81 ng/mL; 1 month, NS, 4 months; 
P , 0.05), sE-selectin (before vs 1 month vs 4 months; 
696 ± 141 vs 688 ± 235 vs 579 ± 128 ng/mL; 1 month, NS; 
4 months, P , 0.05), and sL-selectin (before vs 1 month 
vs 4 months; 631 ± 195 vs 620 ± 139 vs 562 ± 124 ng/mL; 
1 month, NS; 4 months, P , 0.05) (Figure 1). On the 
other hand, miglitol therapy led to a significant increase in 
adiponectin levels after 4 months compared with baseline 
(before vs 1 month vs 4 months; 2.41 ± 1.22 vs 2.82 ± 1.34 
vs 4.63 ± 1.85 µg/mL; 1 month, NS; 4 months, P , 0.01) 
(Figure 1).
Table 2 Levels of PDMP, scD40 L, adiponectin, and selectins in 
patients with hypertension, hyperlipidemia, or type 2 diabetes
Hypertension Hyperlipidemia Diabetes
PDMP, U/mL 13.9 ± 4.6 16.4 ± 5.9a 21.2 ± 7.6b
scD40 L, ng/mL   1.8 ± 0.7   2.2 ± 1.0a   3.1 ± 1.2c
sP-selectin, ng/mL  136 ± 74  155 ± 83a  213 ± 98b
se-selectin, ng/mL    65 ± 31    79 ± 44a    96 ± 41c
sL-selectin, ng/mL  512 ± 160  574 ± 172a  631 ± 195c
Adiponectin, µg/mL 5.32 ± 0.93 3.84 ± 1.04c 2.41 ± 1.22b
Notes:  aNot significant;  bP , 0.01;  cP , 0.05; Data are shown as the mean ± 
standard deviation.
Abbreviations:  PDMP,  platelet-derived  microparticle;  scD40  L,  soluble  cD40 
ligand;  sP-selectin,  soluble  P-selectin;  se-selectin,  soluble  e-selectin;  sL-selectin, 
soluble L-selectin.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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We divided the patients of the diabetes group into two 
subgroups (responders and nonresponders) according to their 
adiponectin response to miglitol treatment. Responders were 
defined as those patients in whom the plasma adiponectin 
levels increased by one and a half times or more after miglitol 
treatment as compared with pretreatment levels. The plasma 
values of PDMP and sCD40L in the two groups are shown 
in Figure 2. Significant decreases in the plasma PDMP and 
sCD40L levels were observed in the responder group after 
miglitol treatment (PDMP before treatment vs after treatment: 
responder group 22.3 ± 6.4 vs 16.8 ± 6.6 U/mL, P , 0.01; 
  nonresponder group 19.4 ± 5.9 vs 18.6 ± 6.3 U/mL, NS, 
ANOVA; responder group vs nonresponder group P , 0.05. 
sCD40L before treatment vs after treatment: responder group 
3.4 ± 1.3 vs 2.5 ± 1.2 ng/mL, P , 0.05; nonresponder group 
3.0 ± 1.6 vs 2.7 ± 1.7 ng/mL, NS, ANOVA; responder vs 
nonresponder, P , 0.05). The plasma values of selectins in the 
two groups are also shown in Figure 2. Significant decreases in 
plasma sP-selectin, sE-selectin, and sL-selectin were observed 
after miglitol treatment in the responder group (sP-selectin 
before treatment vs after treatment: responder group 229 ± 88 
vs 176 ± 75 ng/mL, P , 0.01; nonresponder group: 203 ± 85 
vs 188 ± 87 ng/mL, NS, ANOVA; responder group vs non-
responder group P , 0.05. sE-selectin before treatment vs 
after treatment: responder group 102 ± 44 vs 81 ± 39 ng/mL, 
P , 0.05; nonresponder group 93 ± 38 vs 88 ± 40 ng/mL, NS, 
ANOVA; responder group vs nonresponder group, P , 0.05. 
sL-selectin before treatment vs after treatment: responder 
group 649 ± 188 vs 576 ± 175 ng/mL, P , 0.05; nonresponder 
group 613 ± 156 vs 592 ± 163 ng/mL, NS, ANOVA; responder 
group vs nonresponder group P , 0.05).
Discussion
PDMPs play an important role in the clotting process, so an 
increase in PDMPs is likely to cause hypercoagulability.20 
We previously reported that PDMP levels were significantly 
increased in diabetic patients.21 Because PDMPs promote the 
expression of adhesion molecules by monocytes and endothe-
lial cells,22 it seems possible that these microparticles may 
participate in the development or progression of atheroscle-
rosis in diabetics. Strong antiplatelet drugs such as cilostazol 
or ticlopidine can inhibit the elevation of PDMP,23–25 but the 
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use of these agents for primary prevention of atherothrombo-
sis is problematic. Thus, a new strategy is needed for diabetic 
patients who are highly susceptible to atherothrombosis. 
In the present study, miglitol therapy significantly decreased 
plasma PDMP levels. Although no direct changes in platelet 
function were shown, miglitol therapy also improved another 
platelet activation marker (sCD40L) in our patients with 
diabetes. Postprandial hyperglycemia may be related to 
the activation of platelets in diabetic patients. Postprandial 
hyperglycemia induces oxidative stress via various biochem-
ical pathways, and generation of superoxide occurs, which 
reacts with nitric oxide (NO) to form peroxynitrite.26 The 
resulting decrease in NO levels and activity could accelerate 
vascular inflammation and platelet activation by enhancing 
the expression of various cytokines and growth factors.27 
Thus, our results indicate that postprandial hyperglycemia 
causes platelet activation and endothelial dysfunction. 
Treatment with miglitol significantly reduces body mass 
index and waist circumference.28,29 It has also been reported 
that miglitol prevents nephropathic complication in type 2 
diabetic patients.29 Our results could explain one of the 
mechanisms involved.
The plasma level of adiponectin is decreased in obese 
individuals30 and is closely related to whole-body insulin 
sensitivity.31 A significant decrease in plasma adiponectin 
is also found in patients with type 2 diabetes.31 Adiponectin 
has been reported to suppress the attachment of monocytes 
to endothelial cells27 and plays a role in the protection against 
vascular injury, so hypoadiponectinemia is associated with 
endothelial dysfunction.32 Hypoadiponectinemia also seems 
to cause platelet activation. The level of NO, which regulates 
platelet activation, is decreased by hypoadiponectinemia 
because adiponectin stimulates NO production by vascular 
endothelial cells.33–35 Thus, platelet activation occurs due to 
low NO concentrations in persons with hypoadiponectemia. 
Therefore, the increase in adiponectin by miglitol may have 
an antiplatelet effect via the promotion of NO production. 
Recently, it has been shown that various posttranslational 
modifications, including glycosylation of lysine residues, 
are necessary for the multimerization of adiponectin to 
occur.36 Such intracellular post-translational processes 
may be affected by hyperglycemia, leading to functional 
impairment at the organ level in diabetic patients.37–39 
Therefore, the improvement in postprandial hyperglycemia 
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by miglitol could alter the post-translational modification 
of adiponectin.
In the present study, we found that miglitol caused the 
reduction of sP-selectin, sE-selectin, and sL-selectin. When 
the patients in the diabetes group were divided into two 
subgroups according to the adiponectin response to miglitol 
treatment, a significant decrease in plasma levels of selec-
tins were found after miglitol treatment in the adiponectin 
responder group. In addition, similar results were also 
found for plasma PDMP and sCD40L. These results suggest 
that miglitol causes adiponectin-dependent improvement 
in the plasma levels of selectins, PDMP, and sCD40L in 
diabetic patients.
The exact mechanism by which miglitol treatment leads 
to an increase in circulating adiponectin levels remains 
unclear. We postulate the participation of the gut-derived 
incretin hormone, glucagon-like peptide 1 (GLP-1), for the 
mechanism underlying adiponectin elevation by miglitol 
treatment. Recently, the glucose-lowering and anti-obesity 
effects of GLP-1-based therapies for type 2 diabetes have 
been extensively evaluated.40 One of the antidiabetic effects 
of miglitol depends on GLP-1, because miglitol can enhance 
active GLP-1 secretion.28 In addition, some studies show that 
GLP-1 could promote adiponectin secretion.41,42 We believe 
that the effect of miglitol on selectins and platelet activation 
marker activity depends on adiponectin. Therefore, miglitol 
could inhibit the progression of atherothrombosis by pro-
moting adiponectin-dependent improvement of the plasma 
selectins, PDMP, and sCD40L. However, further studies 
are necessary to elucidate the effects of miglitol itself on 
adiponectin production.
In conclusion, miglitol increased circulating adiponectin 
levels in patients with type 2 diabetes. In addition, miglitol 
treatment led to a decrease in platelet activation markers and 
selectins. Miglitol may be beneficial for primary prevention of 
atherothrombosis in patients with type 2 diabetes.   However, 
a large clinical trial to test this hypothesis is required.
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